Estrogen-progestogen replacement therapy and ovarian cancer: an update.
Hormone replacement therapy in menopause has been associated with a moderate increase in ovarian cancer risk. Data on combined estrogen-progestin therapy, based on one randomized trial, two cohort and four case-control studies, do not provide definite evidence of an association between combined hormone replacement therapy and ovarian cancer. These data do not suggest, however, substantial differences between the effect of estrogen only or unspecified hormone replacement therapy and combined hormone replacement therapy on ovarian cancer risk.
La Vecchia
Carlo
C
Istituto di Ricerche Farmacologiche Mario Negri, Università degli Studi di Milano, Milan, Italy. lavecchia@marionegri.it
D000328:Adult; D016022:Case-Control Studies; D015331:Cohort Studies; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000139:chemically induced*; D012306:Risk